On October 6, 2025, Telomir Pharmaceuticals announced findings showing that Telomir-1 can reset DNA methylation of critical tumor suppressor genes, MASPIN and RASSF1A, potentially fighting treatment resistance and metastasis in aggressive prostate cancer models. This breakthrough suggests a new approach to enhance the body's natural defenses against cancer.